Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) investors will be delighted, with the company turning in some strong numbers with its latest results. Dr. Sulaiman Al Habib Medical Services Group beat earnings, with revenues hitting ر.س4.0b, ahead of expectations, and statutory earnings per share outperforming analyst reckonings by a solid 14%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Taking into account the latest results, the most recent consensus for Dr. Sulaiman Al Habib Medical Services Group from twelve analysts is for revenues of ر.س15.5b in 2026. If met, it would imply a credible 6.2% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to increase 5.7% to ر.س7.31. Before this earnings report, the analysts had been forecasting revenues of ر.س15.4b and earnings per share (EPS) of ر.س7.35 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

The analysts reconfirmed their price target of ر.س270, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Dr. Sulaiman Al Habib Medical Services Group analyst has a price target of ر.س310 per share, while the most pessimistic values it at ر.س188. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Dr. Sulaiman Al Habib Medical Services Group'shistorical trends, as the 13% annualised revenue growth to the end of 2026 is roughly in line with the 16% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 11% annually. So although Dr. Sulaiman Al Habib Medical Services Group is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ر.س270, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Dr. Sulaiman Al Habib Medical Services Group going out to 2028, and you can see them free on our platform here.

Sulaiman Al Habib Medical Services Group that you need to take into consideration.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.